202 related articles for article (PubMed ID: 9160765)
21. Hemodynamic responses to converting enzyme inhibition in patients with renal disease.
August P; Cody RJ; Sealey JE; Laragh JH
Am J Hypertens; 1989 Aug; 2(8):599-603. PubMed ID: 2550029
[TBL] [Abstract][Full Text] [Related]
22. Effects of enalapril and isradipine alone and in combination on blood pressure, renal function and echocardiographic parameters in mild hypertension.
De Rosa ML; Maddaluno G; Lionetti F; Di Palma U; Albanese L; Cardace P; Baiano A; Vigorito C
Int J Cardiol; 2000 Jun; 74(1):77-84. PubMed ID: 10854683
[TBL] [Abstract][Full Text] [Related]
23. Repetitive natriuresis and blood pressure. Long-term calcium entry blockade with isradipine.
Krusell LR; Jespersen LT; Schmitz A; Thomsen K; Pedersen OL
Hypertension; 1987 Dec; 10(6):577-81. PubMed ID: 2447016
[TBL] [Abstract][Full Text] [Related]
24. Effects of long-term administration of isradipine on renal hemodynamics and sodium metabolism.
Francischetti EA; Barroso I; da Silva A; Fagundes VG
J Cardiovasc Pharmacol; 1992; 19 Suppl 3():S90-2. PubMed ID: 1376847
[TBL] [Abstract][Full Text] [Related]
25. Vasoconstriction during acute hypervolemic hemodilution in hypertensive patients is not prevented by calcium blockade.
Wysocki M; Andersson OK; Persson B; Bagge U
Angiology; 1998 Jan; 49(1):41-8. PubMed ID: 9456163
[TBL] [Abstract][Full Text] [Related]
26. Comparison of isradipine and enalapril effects on regional carotid circulation in patients with hypertension with unilateral internal carotid artery stenosis.
Akopov SE; Simonian NA
J Cardiovasc Pharmacol; 1997 Nov; 30(5):562-70. PubMed ID: 9388037
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of slow-release oral isradipine in moderate-to-severe hypertension with add-on spirapril.
Abarquez RF; Sy RG; Castillo RR
Am J Hypertens; 1993 Mar; 6(3 Pt 2):77S-79S. PubMed ID: 8466734
[TBL] [Abstract][Full Text] [Related]
28. ACE-inhibition and renoprotection in early diabetic nephropathy. Response to enalapril acutely and in long-term combination with conventional antihypertensive treatment.
Pedersen MM; Christensen CK; Hansen KW; Christiansen JS; Mogensen CE
Clin Invest Med; 1991 Dec; 14(6):642-51. PubMed ID: 1665407
[TBL] [Abstract][Full Text] [Related]
29. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy.
Andersen S; Tarnow L; Rossing P; Hansen BV; Parving HH
Kidney Int; 2000 Feb; 57(2):601-6. PubMed ID: 10652037
[TBL] [Abstract][Full Text] [Related]
30. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.
Jacobsen P; Andersen S; Rossing K; Jensen BR; Parving HH
Kidney Int; 2003 May; 63(5):1874-80. PubMed ID: 12675866
[TBL] [Abstract][Full Text] [Related]
31. Renal and hemodynamic effects of isradipine in essential hypertension.
Persson B; Andersson OK; Wysocki M; Hedner T; Aurell M
Am J Med; 1989 Apr; 86(4A):60-4. PubMed ID: 2523657
[TBL] [Abstract][Full Text] [Related]
32. Antihypertensive and renal effects of isradipine in essential hypertension: focus on renin system activity.
Allikmets K; Parik T; Teesalu R
Angiology; 1997 Nov; 48(11):977-83. PubMed ID: 9373050
[TBL] [Abstract][Full Text] [Related]
33. The effect of fenoldopam on renal haemodynamics and natriuresis in chronic renal failure.
de Fijter CW; Comans EF; de Vries PM; Oe PL; Roos JC; Smit AJ; Streurman O; Donker AJ
Neth J Med; 1990 Jun; 36(5-6):267-78. PubMed ID: 1975651
[TBL] [Abstract][Full Text] [Related]
34. Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension.
Delles C; Jacobi J; John S; Fleischmann I; Schmieder RE
Kidney Int; 2002 Apr; 61(4):1462-8. PubMed ID: 11918753
[TBL] [Abstract][Full Text] [Related]
35. Are angiotensin converting enzyme inhibitors superior to beta blockers in retarding progressive renal function decline?
van Essen GG; Apperloo AJ; Rensma PL; Stegeman CA; Sluiter WJ; de Zeeuw D; de Jong PE
Kidney Int Suppl; 1997 Dec; 63():S58-62. PubMed ID: 9407423
[TBL] [Abstract][Full Text] [Related]
36. Renal effects of the new calcium channel blocking drug isradipine.
Krämer BK; Häussler M; Ress KM; Müller GA; Burger KJ; Risler T
Eur J Clin Pharmacol; 1990; 39(4):333-5. PubMed ID: 2150190
[TBL] [Abstract][Full Text] [Related]
37. Effects of isradipine or enalapril on blood pressure in salt-sensitive hypertensives during low and high dietary salt intake. MIST II Trial Investigators.
Chrysant SG; Weder AB; McCarron DA; Canossa-Terris M; Cohen JD; Gunter PA; Hamilton BP; Lewin AJ; Mennella RF; Kirkegaard LW; Weir MR; Weinberger MH
Am J Hypertens; 2000 Nov; 13(11):1180-8. PubMed ID: 11078178
[TBL] [Abstract][Full Text] [Related]
38. Renal haemodynamics and function in weanling rats treated with enalapril from birth.
Guron G
Clin Exp Pharmacol Physiol; 2005 Oct; 32(10):865-70. PubMed ID: 16173949
[TBL] [Abstract][Full Text] [Related]
39. Changes in renal resistive index and urinary albumin excretion in hypertensive patients under long-term treatment with lisinopril or nifedipine GITS.
Leoncini G; Martinoli C; Viazzi F; Ravera M; Parodi D; Ratto E; Vettoretti S; Tomolillo C; Derchi LE; Deferrari G; Pontremoli R
Nephron; 2002 Feb; 90(2):169-73. PubMed ID: 11818701
[TBL] [Abstract][Full Text] [Related]
40. Time-dependent effect of isradipine on the nocturnal hypertension in chronic renal failure.
Portaluppi F; Vergnani L; Manfredini R; degli Uberti EC; Fersini C
Am J Hypertens; 1995 Jul; 8(7):719-26. PubMed ID: 7546498
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
